

DR ELIOT BOURK, FORMER KITE PHARMA SENIOR EXECUTIVE, JOINS CHIMERIC AS VP BUSINESS & CORPORATE DEVELOPMENT

HIGHLIGHTS

- Dr Bourk joins Chimeric to drive the growth of its pipeline by advancing strategic business opportunities, initiatives and partnerships
 - Dr Bourk brings extensive cell therapy experience, most recently from Kite Pharma where he was the commercial lead for a portfolio of early-stage cell therapy pipeline assets and for business development strategies and transactions
 - Prior to joining Kite, Dr Bourk spent several years focused on the cell therapy development at Celgene Corporation, where he was the commercial lead for the development of next generation platforms in addition to his role developing Celgene's global CAR T commercial strategy, commercial operations and insights
-

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a clinical stage cell therapy company focused on bringing the promise of cell therapy to patients with cancer, is pleased to announce the appointment of Dr Eliot Bourk as its Vice President, Business and Corporate Development.

Dr Bourk joins Chimeric from Kite Pharmaceuticals where he led early commercial strategy, responsible for the optimisation of a portfolio of early-stage cell therapy pipeline assets and for guiding business development strategies and transactions. Within this role, Dr Bourk guided product development decisions to maximise future commercial opportunity, led the development of corporate disease strategies for solid tumors and hematological malignancies and partnered with translational research teams to focus research and development efforts.

Additionally at Kite, Dr Bourk was instrumental in defining the business development priorities for solid tumors and hematological malignancies, building academic and industry partnerships to identify opportunities and leading commercial diligence for all transactions.

Prior to joining Kite, Dr Bourk was a founding member of the cell therapy commercial team at Celgene Corporation. During his time at Celgene, Dr Bourk was the commercial lead for the development of next generation CAR T platforms, working in partnership with research, development and technical operations to provide commercial insight to guide development and investment in next generation technologies.

At Celgene, Dr Bourk also was instrumental in the development of the Celgene global CAR T commercial strategy including the development and implementation of the cell therapy commercial model.

In his role at Chimeric, Dr Bourk will lead business and corporate development with a near-term focus on enhancing Chimeric's pipeline with additional novel cell therapies.

Chimeric's Executive Chairman Paul Hopper said: "We're very fortunate to have Dr Bourk joining us. His background in cell therapy development will be critical to advancing Chimeric's growth with new and novel cell therapy assets, optimised for commercialisation. His extensive cell therapy experience further complements the cell therapy expertise of our leadership team that we believe is critical to our long term success in cell therapy."

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer.

Chimeric believes that cellular therapies have the potential to cure cancer and that by combining the Company's expertise in the development and commercialisation of cell therapies with the world's most innovative scientists and science, Chimeric will be able to bring the promise of cell therapy to life for more patients.

Chimeric Therapeutics is currently in a phase 1 clinical trial for its lead asset, CLTX-CAR T.

CLTX-CAR T is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM), developed by scientists at the City of Hope Medical Centre in California. CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models while CLTX-CAR T cells were not shown to exhibit off-tumor recognition of normal human or murine cells/tissues, supporting a potential optimal safety profile.

Chimeric Therapeutics is now actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au